Notes to consolidated financial statements

4,669
22,915
(Income) Expense not allocated to segments
6,202
5,972
7,853
Worldwide total
32,581
16,687
15,062
Identifiable Assets
(Dollars in Millions)
Innovative Medicine
78,057
57,070
MedTech
86,482
84,322
Total
164,539
141,392
General corporate
34,671
38,712
Worldwide total
199,210
180,104
Additions to Property,
Plant & Equipment
Depreciation and
Amortization
(Dollars in Millions)
Innovative Medicine
2,076
1,710
1,653
3,772
3,760
3,847
MedTech
2,501
2,443
2,372
3,490
3,237
2,943
Segments total
4,577
4,153
4,025
7,262
6,997
6,790
Discontinued operations
General corporate
Worldwide total
4,832
4,424
4,543
7,503
7,339
7,486
2025 Annual Report
Sales to Customers
Long-Lived Assets
(Dollars in Millions)
United States
53,752
50,302
46,444
89,392
70,670
Europe
21,535
20,212
20,410
27,987
27,267
Western Hemisphere excluding U.S.
4,875
4,714
4,549
2,204
1,728
Asia-Pacific, Africa
14,031
13,593
13,756
1,544
1,454
Segments total
94,193
88,821
85,159
121,127
101,119
General corporate
1,217
Other non long-lived assets
76,866
77,768
Worldwide total
94,193
88,821
85,159
199,210
180,104
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In fiscal year 2025, the Company utilized three wholesalers distributing products for both segments that represented approximately
21.8
15.5
% and
11.1
% of the total gross revenues. In fiscal year 2024, the Company had three wholesalers distributing products for both segments that represented approximately
20.5
15.6
% and
12.3
% of the total gross revenues. In fiscal year 2023, the Company had three wholesalers distributing products for both segments that represented approximately
18.2
15.1
%, and
14.2
% of the total gross revenues.
Other segment expenses
for each reportable segment include charges related to other income and expenses, restructuring activities and impairment charges related to in-process research and development.
Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal year 2025 includes the reversal of approximately $
billion, a significant portion of the previously accrued talc reserve. The fiscal years 2024 and 2023 include charges for talc matters of approximately $
billion and $
billion, respectively (See Note 19, Legal proceedings, for additional details). The fiscal year 2024 includes a loss of approximately $
billion related to the debt to equity exchange of the Company's remaining shares of Kenvue Common Stock. The fiscal year 2023 includes the unfavorable change in the fair value of the retained stake in Kenvue of approximately $
billion.
Innovative Medicine segment income before tax includes:

Question: What was Johnson & Johnson's revenue in fiscal year 2025?

revenue from contract with customer excluding assessed tax

what was johnson & johnson's revenue in fiscal year 2025?

4669 22915 (income) expense not allocated to segments 6202 5972 7853 worldwide total 32581 16687 15062 identifiable assets (dollars in millions) innovative medicine 78057 57070 medtech 86482 84322 total 164539 141392 general corporate 34671 38712 worldwide total 199210 180104 additions to property plant & equipment depreciation and amortization (dollars in millions) innovative medicine 2076 1710 1653 3772 3760 3847 medtech 2501 2443 2372 3490 3237 2943 segments total 4577 4153 4025 7262 6997 6790 discontinued operations general corporate worldwide total 4832 4424 4543 7503 7339 7486 2025 annual report sales to customers long-lived assets (dollars in millions) united states 53752 50302 46444 89392 70670 europe 21535 20212 20410 27987 27267 western hemisphere excluding u.s. 4875 4714 4549 2204 1728 asia-pacific africa 14031 13593 13756 1544 1454 segments total 94193 88821 85159 121127 101119 general corporate 1217 other non long-lived assets 76866 77768 worldwide total 94193 88821 85159 199210 180104 see note 1 for a description of the segments in which the company operates. export sales are not significant. in fiscal year 2025 the company utilized three wholesalers distributing products for both segments that represented approximately 21.8 15.5 % and 11.1 % of the total gross revenues. in fiscal year 2024 the company had three wholesalers distributing products for both segments that represented approximately 20.5 15.6 % and 12.3 % of the total gross revenues. in fiscal year 2023 the company had three wholesalers distributing products for both segments that represented approximately 18.2 15.1 % and 14.2 % of the total gross revenues. other segment expenses for each reportable segment include charges related to other income and expenses restructuring activities and impairment charges related to in-process research and development. amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. the fiscal year 2025 includes the reversal of approximately billion a significant portion of the previously accrued talc reserve. the fiscal years 2024 and 2023 include charges for talc matters of approximately billion and billion respectively (see note 19 legal proceedings for additional details). the fiscal year 2024 includes a loss of approximately billion related to the debt to equity exchange of the company's remaining shares of kenvue common stock. the fiscal year 2023 includes the unfavorable change in the fair value of the retained stake in kenvue of approximately billion. innovative medicine segment income before tax includes:


Johnson & Johnson and subsidiaries consolidated balance sheets

At December 28, 2025 and December 29, 2024
(Dollars in Millions Except Share and Per Share Amounts) (Note 1)
Assets
Current assets
Cash and cash equivalents (Notes 1 and 2)
19,709
24,105
Marketable securities (Notes 1 and 2)
Accounts receivable trade, less allowances $
(2024, $
17,178
14,842
Inventories (Notes 1 and 3)
14,191
12,444
Prepaid expenses and other receivables
4,153
4,085
Total current assets
55,624
55,893
Property, plant and equipment, net (Notes 1 and 4)
23,169
20,518
Intangible assets, net (Notes 1 and 5)
50,403
37,618
Goodwill (Notes 1 and 5)
48,772
44,200
Deferred taxes on income (Note 8)
6,874
10,461
Other assets
14,368
11,414
Total assets
199,210
180,104
Liabilities and Shareholders’ Equity
Current liabilities
Loans and notes payable (Note 7)
8,495
5,983
Accounts payable
11,991
10,311
Accrued liabilities
8,594
8,549
Accrued rebates, returns and promotions
19,124
17,580
Accrued compensation and employee related obligations
4,534
4,126
Accrued taxes on income (Note 8)
1,388
3,772
Total current liabilities
54,126
50,321
Long-term debt (Note 7)
39,438
30,651
Deferred taxes on income (Note 8)
6,791
2,448
Employee related obligations (Notes 9 and 10)
6,957
7,255
Long-term taxes payable (Note 1)
Other liabilities
9,868
17,549
Total liabilities
117,666
108,614
Commitments and Contingencies (Note 19)
Shareholders’ equity
Preferred stock — without par value (authorized and unissued
2,000,000
shares)
Common stock — par value $
1.00
per share (Note 12) (authorized
4,320,000,000
shares; issued
3,119,843,000
shares)
3,120
Accumulated other comprehensive income (loss) (Note 13)
14,930
11,741
Retained earnings and Additional-paid-in-capital
168,978
155,791
Less: common stock held in treasury, at cost (Note 12) (
711,904,000
shares and
712,921,000
shares)
75,624
75,680
Total shareholders’ equity
81,544
71,490
Total liabilities and shareholders’ equity
199,210
180,104
See Notes to Consolidated Financial Statements
2025 Annual Report

Question: What was Johnson & Johnson's total assets in fiscal year 2025?

what was johnson & johnson's total assets in fiscal year 2025?

what was total assets in fiscal year 2025?

at december 28 2025 and december 29 2024 (dollars in millions except share and per share amounts) (note 1) assets current assets cash and cash equivalents (notes 1 and 2) 19709 24105 marketable securities (notes 1 and 2) accounts receivable trade less allowances (2024 17178 14842 inventories (notes 1 and 3) 14191 12444 prepaid expenses and other receivables 4153 4085 total current assets 55624 55893 property plant and equipment net (notes 1 and 4) 23169 20518 intangible assets net (notes 1 and 5) 50403 37618 goodwill (notes 1 and 5) 48772 44200 deferred taxes on income (note 8) 6874 10461 other assets 14368 11414 total assets 199210 180104 liabilities and shareholders' equity current liabilities loans and notes payable (note 7) 8495 5983 accounts payable 11991 10311 accrued liabilities 8594 8549 accrued rebates returns and promotions 19124 17580 accrued compensation and employee related obligations 4534 4126 accrued taxes on income (note 8) 1388 3772 total current liabilities 54126 50321 long-term debt (note 7) 39438 30651 deferred taxes on income (note 8) 6791 2448 employee related obligations (notes 9 and 10) 6957 7255 long-term taxes payable (note 1) other liabilities 9868 17549 total liabilities 117666 108614 commitments and contingencies (note 19) shareholders' equity preferred stock — without par value (authorized and unissued 2000000 shares) common stock — par value 1.00 per share (note 12) (authorized 4320000000 shares; issued 3119843000 shares) 3120 accumulated other comprehensive income (loss) (note 13) 14930 11741 retained earnings and additional-paid-in-capital 168978 155791 less: common stock held in treasury at cost (note 12) ( 711904000 shares and 712921000 shares) 75624 75680 total shareholders' equity 81544 71490 total liabilities and shareholders' equity 199210 180104 see notes to consolidated financial statements 2025 annual report


Johnson & Johnson and subsidiaries consolidated statements of earnings

(Dollars and Shares in Millions Except Per Share Amounts) (Note 1)
Sales to customers
94,193
88,821
85,159
Cost of products sold
30,256
27,471
26,553
Gross profit
63,937
61,350
58,606
Selling, marketing and administrative expenses
23,676
22,869
21,512
Research and development expense
14,665
17,232
15,085
In-process research and development impairments
Interest income
1,056
1,332
1,261
Interest expense, net of portion capitalized (Note 4)
Other (income) expense, net
7,209
4,694
6,634
Restructuring (Note 20)
Earnings before provision for taxes on income
32,581
16,687
15,062
Provision for taxes on income (Note 8)
5,777
2,621
1,736
Net earnings from continuing operations
26,804
14,066
13,326
Net earnings from discontinued operations, net of tax (Note 21)
21,827
Net earnings
26,804
14,066
35,153
Net earnings per share (Notes 1 and 15)
Continuing operations - basic
11.13
5.84
5.26
Discontinued operations - basic
8.62
Total net earnings per share - basic
11.13
5.84
13.88
Continuing operations - diluted
11.03
5.79
5.20
Discontinued operations - diluted
8.52
Total net earnings per share - diluted
11.03
5.79
13.72
Average shares outstanding (Notes 1 and 15)
Basic
2,407.4
2,407.3
2,533.5
Diluted
2,429.4
2,560.4
See Notes to Consolidated Financial Statements

Question: What was Johnson & Johnson's gross margin in fiscal year 2025?

what was johnson & johnson's gross margin in fiscal year 2025?

(dollars and shares in millions except per share amounts) (note 1) sales to customers 94193 88821 85159 cost of products sold 30256 27471 26553 gross profit 63937 61350 58606 selling marketing and administrative expenses 23676 22869 21512 research and development expense 14665 17232 15085 in-process research and development impairments interest income 1056 1332 1261 interest expense net of portion capitalized (note 4) other (income) expense net 7209 4694 6634 restructuring (note 20) earnings before provision for taxes on income 32581 16687 15062 provision for taxes on income (note 8) 5777 2621 1736 net earnings from continuing operations 26804 14066 13326 net earnings from discontinued operations net of tax (note 21) 21827 net earnings 26804 14066 35153 net earnings per share (notes 1 and 15) continuing operations - basic 11.13 5.84 5.26 discontinued operations - basic 8.62 total net earnings per share - basic 11.13 5.84 13.88 continuing operations - diluted 11.03 5.79 5.20 discontinued operations - diluted 8.52 total net earnings per share - diluted 11.03 5.79 13.72 average shares outstanding (notes 1 and 15) basic 2407.4 2407.3 2533.5 diluted 2429.4 2560.4 see notes to consolidated financial statements


Question: What was Johnson & Johnson's net margin in fiscal year 2025?

what was johnson & johnson's net margin in fiscal year 2025?


Johnson & Johnson and subsidiaries consolidated statements of cash flows

(Dollars in Millions) (Note 1)
Cash flows from operating activities
Net earnings
26,804
14,066
35,153
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles
7,503
7,339
7,486
Stock based compensation
1,354
1,176
1,162
Asset write-downs
1,295
Charges for acquired in-process research and development
1,841
Gain on Kenvue separation
20,984
Net gain on sale of assets/businesses
Deferred tax provision
1,538
2,183
4,194
Credit losses and accounts receivable allowances
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable
1,781
Increase in inventories
1,450
1,128
1,323
Increase in accounts payable and accrued liabilities
2,377
1,621
2,346
(Increase)/Decrease in other current and non-current assets
6,167
1,717
3,480
(Decrease)/Increase in other current and non-current liabilities
5,697
5,588
Net cash flows from operating activities
24,530
24,266
22,791
Cash flows (used by) from investing activities
Additions to property, plant and equipment
4,832
4,424
4,543
Proceeds from the disposal of assets/businesses, net
Acquisitions, net of cash acquired (Note 18)
17,541
15,146
Acquired in-process research and development/related milestones (Note 18)
1,783
Purchases of investments
1,726
10,906
Sales of investments
1,661
2,462
19,390
Credit support agreements activity, net
2,129
1,517
2,963
Other (including capitalized licenses and milestones)
Net cash (used by)/from investing activities
23,588
18,599
Cash flows (used by) from financing activities
Dividends to shareholders
12,381
11,823
11,770
Repurchase of common stock
5,953
2,432
5,054
Proceeds from short-term debt
14,586
15,277
13,743
Repayment of short-term debt
12,330
9,463
22,973
Proceeds from long-term debt, net of issuance costs
9,138
6,660
Repayment of long-term debt
1,757
1,453
1,551
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net
3,418
1,094
Credit support agreements activity, net
2025 Annual Report
Settlement of convertible debt acquired from Shockwave
Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to Kenvue at separation
8,047
Proceeds from Kenvue initial public offering
4,241
Cash transferred to Kenvue at separation
1,114
Other
Net cash used by financing activities
5,539
3,132
15,825
Effect of exchange rate changes on cash and cash equivalents
(Decrease)/Increase in cash and cash equivalents
4,396
2,246
7,732
Cash and cash equivalents from continuing operations, beginning of period
24,105
21,859
12,889
Cash and cash equivalents from discontinued operations, beginning of period
1,238
Cash and cash equivalents, beginning of year (Note 1)
24,105
21,859
14,127

Question: What was Johnson & Johnson's operating cash flow margin in fiscal year 2025?

what was johnson & johnson's operating cash flow margin in fiscal year 2025?

(dollars in millions) (note 1) cash flows from operating activities net earnings 26804 14066 35153 adjustments to reconcile net earnings to cash flows from operating activities: depreciation and amortization of property and intangibles 7503 7339 7486 stock based compensation 1354 1176 1162 asset write-downs 1295 charges for acquired in-process research and development 1841 gain on kenvue separation 20984 net gain on sale of assets/businesses deferred tax provision 1538 2183 4194 credit losses and accounts receivable allowances changes in assets and liabilities net of effects from acquisitions and divestitures: increase in accounts receivable 1781 increase in inventories 1450 1128 1323 increase in accounts payable and accrued liabilities 2377 1621 2346 (increase)/decrease in other current and non-current assets 6167 1717 3480 (decrease)/increase in other current and non-current liabilities 5697 5588 net cash flows from operating activities 24530 24266 22791 cash flows (used by) from investing activities additions to property plant and equipment 4832 4424 4543 proceeds from the disposal of assets/businesses net acquisitions net of cash acquired (note 18) 17541 15146 acquired in-process research and development/related milestones (note 18) 1783 purchases of investments 1726 10906 sales of investments 1661 2462 19390 credit support agreements activity net 2129 1517 2963 other (including capitalized licenses and milestones) net cash (used by)/from investing activities 23588 18599 cash flows (used by) from financing activities dividends to shareholders 12381 11823 11770 repurchase of common stock 5953 2432 5054 proceeds from short-term debt 14586 15277 13743 repayment of short-term debt 12330 9463 22973 proceeds from long-term debt net of issuance costs 9138 6660 repayment of long-term debt 1757 1453 1551 proceeds from the exercise of stock options/employee withholding tax on stock awards net 3418 1094 credit support agreements activity net 2025 annual report settlement of convertible debt acquired from shockwave proceeds of short and long-term debt net of issuance cost related to the debt that transferred to kenvue at separation 8047 proceeds from kenvue initial public offering 4241 cash transferred to kenvue at separation 1114 other net cash used by financing activities 5539 3132 15825 effect of exchange rate changes on cash and cash equivalents (decrease)/increase in cash and cash equivalents 4396 2246 7732 cash and cash equivalents from continuing operations beginning of period 24105 21859 12889 cash and cash equivalents from discontinued operations beginning of period 1238 cash and cash equivalents beginning of year (note 1) 24105 21859 14127


Question: By what percentage did Johnson & Johnson's net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did johnson & johnson's net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did net income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did Johnson & Johnson's revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did johnson & johnson's revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did revenue change from fiscal year 2024 to fiscal year 2025?


Consolidated Statement of Comprehensive Income (Loss)

Merck & Co., Inc. and Subsidiaries
Years Ended December 31
($ in millions)
Net Income Attributable to Merck & Co., Inc.
18,254
17,117
Other Comprehensive Income (Loss) Net of Taxes:
Net unrealized (loss) income on derivatives, net of reclassifications
Benefit plan net gain (loss) and prior service credit (cost), net of amortization
Cumulative translation adjustment
Comprehensive Income (Loss) Attributable to Merck & Co., Inc.
18,912
17,333
The accompanying notes are an integral part of these consolidated financial statements.

Question: What was Merck & Co., Inc.'s net income in fiscal year 2025?

what was merck & co. inc.'s net income in fiscal year 2025?

what was net income in fiscal year 2025?

merck & co. inc. and subsidiaries years ended december 31 ( in millions) net income attributable to merck & co. inc. 18254 17117 other comprehensive income (loss) net of taxes: net unrealized (loss) income on derivatives net of reclassifications benefit plan net gain (loss) and prior service credit (cost) net of amortization cumulative translation adjustment comprehensive income (loss) attributable to merck & co. inc. 18912 17333 the accompanying notes are an integral part of these consolidated financial statements.


Merck & Co., Inc. and Subsidiaries
Years Ended December 31
($ in millions)
Cash Flows from Operating Activities
Net income
18,263
17,133
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization
2,793
2,395
2,044
Depreciation
3,045
2,104
1,828
Intangible asset impairment charges
Income from investments in equity securities, net
Charges for certain research and development asset acquisitions
3,456
11,409
Deferred income taxes
1,671
1,249
1,899
Share-based compensation
Other
Net changes in assets and liabilities:
Accounts receivable
1,090
1,148
Inventories
1,180
Trade accounts payable
Accrued and other current liabilities
1,841
2,328
1,783
Income taxes payable
1,023
Noncurrent liabilities
Other
3,307
1,416
2,314
Net Cash Provided by Operating Activities
16,472
21,468
13,006
Cash Flows from Investing Activities
Capital expenditures
4,112
3,372
3,863
Purchases of securities and other investments
1,207
Proceeds from sales of securities and other investments
1,678
1,658
Proceeds from sale of Seagen Inc. common stock
1,145
Acquisition of Verona Pharma plc, net of cash acquired
10,042
Acquisition of Eyebiotech Limited, net of cash acquired
1,344
Acquisition of Elanco Animal Health Incorporated aqua business
1,303
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired
Acquisition of MK-1045 from Curon Pharmaceutical
Acquisition of Prometheus Biosciences, Inc., net of cash acquired
10,705
Acquisition of Imago BioSciences Inc., net of cash acquired
1,327
Other
Net Cash Used in Investing Activities
13,741
7,734
14,083
Cash Flows from Financing Activities
Payments on debt
2,503
1,290
1,755
Proceeds from issuance of debt
13,880
3,599
5,939
Purchases of treasury stock
5,084
1,306
1,346
Dividends paid to stockholders
8,176
7,840
7,445
Proceeds from exercise of stock options
Other
Net Cash Used in Financing Activities
1,922
7,032
4,810
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash
1,372
6,409
5,864
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $
and $
of restricted cash at January 1, 2025, 2024 and 2023, respectively, included in
Other current assets
13,318
6,909
12,773
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $
and $
of restricted cash at December 31, 2025, 2024 and 2023, respectively, included in
Other current assets
14,690
13,318
6,909
The accompanying notes are an integral part of this consolidated financial statement.

Question: What was Merck & Co., Inc.'s operating cash flow in fiscal year 2025?

net cash provided by used in operating activities

what was merck & co. inc.'s operating cash flow in fiscal year 2025?

what was operating cash flow in fiscal year 2025?

merck & co. inc. and subsidiaries years ended december 31 ( in millions) cash flows from operating activities net income 18263 17133 adjustments to reconcile net income to net cash provided by operating activities: amortization 2793 2395 2044 depreciation 3045 2104 1828 intangible asset impairment charges income from investments in equity securities net charges for certain research and development asset acquisitions 3456 11409 deferred income taxes 1671 1249 1899 share-based compensation other net changes in assets and liabilities: accounts receivable 1090 1148 inventories 1180 trade accounts payable accrued and other current liabilities 1841 2328 1783 income taxes payable 1023 noncurrent liabilities other 3307 1416 2314 net cash provided by operating activities 16472 21468 13006 cash flows from investing activities capital expenditures 4112 3372 3863 purchases of securities and other investments 1207 proceeds from sales of securities and other investments 1678 1658 proceeds from sale of seagen inc. common stock 1145 acquisition of verona pharma plc net of cash acquired 10042 acquisition of eyebiotech limited net of cash acquired 1344 acquisition of elanco animal health incorporated aqua business 1303 acquisition of harpoon therapeutics inc. net of cash acquired acquisition of mk-1045 from curon pharmaceutical acquisition of prometheus biosciences inc. net of cash acquired 10705 acquisition of imago biosciences inc. net of cash acquired 1327 other net cash used in investing activities 13741 7734 14083 cash flows from financing activities payments on debt 2503 1290 1755 proceeds from issuance of debt 13880 3599 5939 purchases of treasury stock 5084 1306 1346 dividends paid to stockholders 8176 7840 7445 proceeds from exercise of stock options other net cash used in financing activities 1922 7032 4810 effect of exchange rate changes on cash cash equivalents and restricted cash net increase (decrease) in cash cash equivalents and restricted cash 1372 6409 5864 cash cash equivalents and restricted cash at beginning of year (includes and of restricted cash at january 1 2025 2024 and 2023 respectively included in other current assets 13318 6909 12773 cash cash equivalents and restricted cash at end of year (includes and of restricted cash at december 31 2025 2024 and 2023 respectively included in other current assets 14690 13318 6909 the accompanying notes are an integral part of this consolidated financial statement.


Merck & Co., Inc. and Subsidiaries
Years Ended December 31
($ in millions except per share amounts)
Sales
65,011
64,168
60,115
Costs, Expenses and Other
Cost of sales
16,382
15,193
16,126
Selling, general and administrative
10,733
10,816
10,504
Research and development
15,789
17,938
30,531
Restructuring costs
Other (income) expense, net
43,944
44,232
58,226
Income Before Taxes
21,067
19,936
1,889
Taxes on Income
2,804
2,803
1,512
Net Income
18,263
17,133
Less: Net Income Attributable to Noncontrolling Interests
Net Income Attributable to Merck & Co., Inc.
18,254
17,117
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders
7.30
6.76
0.14
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders
7.28
6.74
0.14

Question: What was Merck & Co., Inc.'s revenue in fiscal year 2025?

what was merck & co. inc.'s revenue in fiscal year 2025?

merck & co. inc. and subsidiaries years ended december 31 ( in millions except per share amounts) sales 65011 64168 60115 costs expenses and other cost of sales 16382 15193 16126 selling general and administrative 10733 10816 10504 research and development 15789 17938 30531 restructuring costs other (income) expense net 43944 44232 58226 income before taxes 21067 19936 1889 taxes on income 2804 2803 1512 net income 18263 17133 less: net income attributable to noncontrolling interests net income attributable to merck & co. inc. 18254 17117 basic earnings per common share attributable to merck & co. inc. common shareholders 7.30 6.76 0.14 earnings per common share assuming dilution attributable to merck & co. inc. common shareholders 7.28 6.74 0.14


Merck & Co., Inc. and Subsidiaries
December 31
($ in millions except per share amounts)
Assets
Current Assets
Cash and cash equivalents
14,565
13,242
Short-term investments
Accounts receivable (net of allowance for doubtful accounts of $
in 2025
and $
in 2024)
11,775
10,278
Inventories (excludes inventories of $
5,681
in 2025 and $
4,193
in 2024
classified in Other assets - see Note 7)
6,658
6,109
Other current assets
10,518
8,706
Total current assets
43,516
38,782
Investments
Property, Plant and Equipment (at cost)
Land
Buildings
17,983
16,360
Machinery, equipment and office furnishings
19,760
18,283
Construction in progress
9,166
7,984
47,230
42,934
Less: accumulated depreciation
21,914
19,155
25,316
23,779
Goodwill
21,579
21,668
Other Intangibles, Net
26,681
16,370
Other Assets
18,818
16,044
136,866
117,106
Liabilities and Equity
Current Liabilities
Loans payable and current portion of long-term debt
2,589
2,649
Trade accounts payable
4,404
4,079
Accrued and other current liabilities
14,468
15,694
Income taxes payable
4,726
3,914
Dividends payable
2,140
2,084
Total current liabilities
28,327
28,420
Long-Term Debt
46,750
34,462
Deferred Income Taxes
1,439
1,387
Other Noncurrent Liabilities
7,688
6,465
Merck & Co., Inc. Stockholders’ Equity
Common stock, $
0.50
par value
Authorized -
6,500,000,000
shares
Issued -
3,577,103,522
shares in 2025 and 2024
1,788
Other paid-in capital
45,029
44,704
Retained earnings
73,075
63,069
Accumulated other comprehensive loss
4,287
4,945
115,605
104,616
Less treasury stock, at cost:
1,102,476,756
shares in 2025 and
1,049,466,187
shares in 2024
62,999
58,303
Total Merck & Co., Inc. stockholders’ equity
52,606
46,313
Noncontrolling Interests
Total equity
52,662
46,372
136,866
117,106
The accompanying notes are an integral part of this consolidated financial statement.

Question: What was Merck & Co., Inc.'s total assets in fiscal year 2025?

what was merck & co. inc.'s total assets in fiscal year 2025?

what was total assets in fiscal year 2025?

merck & co. inc. and subsidiaries december 31 ( in millions except per share amounts) assets current assets cash and cash equivalents 14565 13242 short-term investments accounts receivable (net of allowance for doubtful accounts of in 2025 and in 2024) 11775 10278 inventories (excludes inventories of 5681 in 2025 and 4193 in 2024 classified in other assets - see note 7) 6658 6109 other current assets 10518 8706 total current assets 43516 38782 investments property plant and equipment (at cost) land buildings 17983 16360 machinery equipment and office furnishings 19760 18283 construction in progress 9166 7984 47230 42934 less: accumulated depreciation 21914 19155 25316 23779 goodwill 21579 21668 other intangibles net 26681 16370 other assets 18818 16044 136866 117106 liabilities and equity current liabilities loans payable and current portion of long-term debt 2589 2649 trade accounts payable 4404 4079 accrued and other current liabilities 14468 15694 income taxes payable 4726 3914 dividends payable 2140 2084 total current liabilities 28327 28420 long-term debt 46750 34462 deferred income taxes 1439 1387 other noncurrent liabilities 7688 6465 merck & co. inc. stockholders' equity common stock 0.50 par value authorized - 6500000000 shares issued - 3577103522 shares in 2025 and 2024 1788 other paid-in capital 45029 44704 retained earnings 73075 63069 accumulated other comprehensive loss 4287 4945 115605 104616 less treasury stock at cost: 1102476756 shares in 2025 and 1049466187 shares in 2024 62999 58303 total merck & co. inc. stockholders' equity 52606 46313 noncontrolling interests total equity 52662 46372 136866 117106 the accompanying notes are an integral part of this consolidated financial statement.


Question: What was Merck & Co., Inc.'s gross margin in fiscal year 2025?

what was merck & co. inc.'s gross margin in fiscal year 2025?


Question: What was Merck & Co., Inc.'s net margin in fiscal year 2025?

what was merck & co. inc.'s net margin in fiscal year 2025?


Question: What was Merck & Co., Inc.'s operating cash flow margin in fiscal year 2025?

what was merck & co. inc.'s operating cash flow margin in fiscal year 2025?


Question: By what percentage did Merck & Co., Inc.'s net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did merck & co. inc.'s net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did net income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did Merck & Co., Inc.'s revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did merck & co. inc.'s revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did revenue change from fiscal year 2024 to fiscal year 2025?


Consolidated Statement of Comprehensive Income

(in millions)
Year Ended December 31
Net Earnings
6,524
13,402
5,723
Foreign currency translation gain (loss) adjustments, net of taxes of $
in 2025 and $
in 2024 and 2023
1,574
1,001
Net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $
in 2025, $
in 2024, and $
in 2023
Net gains (losses) on derivative instruments designated as cash flow hedges, net of taxes of $(
) in 2025, $
in 2024, and $(
) in 2023
Other Comprehensive Income (Loss)
1,905
Comprehensive Income
8,429
13,335
5,935
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax as of December 31:
Cumulative foreign currency translation (loss) adjustments
5,931
7,505
6,504
Net actuarial (losses) and prior service (cost) and credits
1,376
Cumulative gains (losses) on derivative instruments designated as cash flow hedges
Accumulated other comprehensive income (loss)
6,001
7,906
7,839
The accompanying notes to consolidated financial statements are an integral part of this statement.
Abbott Laboratories and Subsidiaries

Question: What was Abbott Laboratories's net income in fiscal year 2025?

what was abbott laboratories's net income in fiscal year 2025?

what was net income in fiscal year 2025?

(in millions) year ended december 31 net earnings 6524 13402 5723 foreign currency translation gain (loss) adjustments net of taxes of in 2025 and in 2024 and 2023 1574 1001 net actuarial gains (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits net of taxes of in 2025 in 2024 and in 2023 net gains (losses) on derivative instruments designated as cash flow hedges net of taxes of ( ) in 2025 in 2024 and ( ) in 2023 other comprehensive income (loss) 1905 comprehensive income 8429 13335 5935 supplemental accumulated other comprehensive income (loss) information net of tax as of december 31: cumulative foreign currency translation (loss) adjustments 5931 7505 6504 net actuarial (losses) and prior service (cost) and credits 1376 cumulative gains (losses) on derivative instruments designated as cash flow hedges accumulated other comprehensive income (loss) 6001 7906 7839 the accompanying notes to consolidated financial statements are an integral part of this statement. abbott laboratories and subsidiaries


(in millions)
Year Ended December 31
Cash Flow From (Used in) Operating Activities:
Net earnings
6,524
13,402
5,723
Adjustments to reconcile earnings to net cash from operating activities —
Depreciation
1,434
1,340
1,277
Amortization of intangible assets
1,682
1,878
1,966
Share-based compensation
Investing and financing losses, net
Trade receivables
Inventories
Prepaid expenses and other assets
1,295
Trade accounts payable and other liabilities
Income taxes
8,028
Net Cash From Operating Activities
9,566
8,558
7,261
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment
2,171
2,207
2,202
Acquisitions of businesses and technologies, net of cash acquired
Proceeds from business dispositions
Purchases of investment securities
Proceeds from sales of investment securities
Other
Net Cash From (Used in) Investing Activities
2,422
2,338
3,133
Cash Flow From (Used in) Financing Activities:
Proceeds from issuance of (repayments of) short-term debt, net and other
Proceeds from issuance of long-term debt and debt with maturities over 3 months
Repayments of long-term debt and debt with maturities over 3 months
1,504
2,498
Purchases of common shares
1,295
1,227
Proceeds from stock options exercised
Dividends paid
4,116
3,836
3,556
Other
Net Cash From (Used in) Financing Activities
6,309
5,404
7,091
Effect of exchange rate changes on cash and cash equivalents
Net Increase (Decrease) in Cash and Cash Equivalents
2,986
Cash and Cash Equivalents, Beginning of Year
7,616
6,896
9,882
Cash and Cash Equivalents, End of Year
8,522
7,616
6,896
Supplemental Cash Flow Information:
Income taxes paid
1,933
1,723
1,475
Interest paid
The accompanying notes to consolidated financial statements are an integral part of this statement.
Abbott Laboratories and Subsidiaries

Question: What was Abbott Laboratories's operating cash flow in fiscal year 2025?

net cash provided by used in operating activities

what was abbott laboratories's operating cash flow in fiscal year 2025?

what was operating cash flow in fiscal year 2025?

(in millions) year ended december 31 cash flow from (used in) operating activities: net earnings 6524 13402 5723 adjustments to reconcile earnings to net cash from operating activities — depreciation 1434 1340 1277 amortization of intangible assets 1682 1878 1966 share-based compensation investing and financing losses net trade receivables inventories prepaid expenses and other assets 1295 trade accounts payable and other liabilities income taxes 8028 net cash from operating activities 9566 8558 7261 cash flow from (used in) investing activities: acquisitions of property and equipment 2171 2207 2202 acquisitions of businesses and technologies net of cash acquired proceeds from business dispositions purchases of investment securities proceeds from sales of investment securities other net cash from (used in) investing activities 2422 2338 3133 cash flow from (used in) financing activities: proceeds from issuance of (repayments of) short-term debt net and other proceeds from issuance of long-term debt and debt with maturities over 3 months repayments of long-term debt and debt with maturities over 3 months 1504 2498 purchases of common shares 1295 1227 proceeds from stock options exercised dividends paid 4116 3836 3556 other net cash from (used in) financing activities 6309 5404 7091 effect of exchange rate changes on cash and cash equivalents net increase (decrease) in cash and cash equivalents 2986 cash and cash equivalents beginning of year 7616 6896 9882 cash and cash equivalents end of year 8522 7616 6896 supplemental cash flow information: income taxes paid 1933 1723 1475 interest paid the accompanying notes to consolidated financial statements are an integral part of this statement. abbott laboratories and subsidiaries


(in millions except per share data)
Year Ended December 31
Net Sales
44,328
41,950
40,109
Cost of products sold, excluding amortization of intangible assets
19,319
18,706
17,975
Amortization of intangible assets
1,682
1,878
1,966
Research and development
2,942
2,844
2,741
Selling, general and administrative
12,332
11,697
10,949
Total Operating Cost and Expenses
36,275
35,125
33,631
Operating Earnings
8,053
6,825
6,478
Interest expense
Interest income
Net foreign exchange (gain) loss
Other (income) expense, net
Earnings before Taxes
8,466
7,013
6,664
Taxes on Earnings
1,942
6,389
Net Earnings
6,524
13,402
5,723
Basic Earnings Per Common Share
3.73
7.67
3.28
Diluted Earnings Per Common Share
3.72
7.64
3.26
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share
1,741
1,740
Dilutive Common Stock Options
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options
1,748
1,749
Outstanding Common Stock Options Having No Dilutive Effect
The accompanying notes to consolidated financial statements are an integral part of this statement.
Abbott Laboratories and Subsidiaries

Question: What was Abbott Laboratories's revenue in fiscal year 2025?

revenue from contract with customer excluding assessed tax

what was abbott laboratories's revenue in fiscal year 2025?

(in millions except per share data) year ended december 31 net sales 44328 41950 40109 cost of products sold excluding amortization of intangible assets 19319 18706 17975 amortization of intangible assets 1682 1878 1966 research and development 2942 2844 2741 selling general and administrative 12332 11697 10949 total operating cost and expenses 36275 35125 33631 operating earnings 8053 6825 6478 interest expense interest income net foreign exchange (gain) loss other (income) expense net earnings before taxes 8466 7013 6664 taxes on earnings 1942 6389 net earnings 6524 13402 5723 basic earnings per common share 3.73 7.67 3.28 diluted earnings per common share 3.72 7.64 3.26 average number of common shares outstanding used for basic earnings per common share 1741 1740 dilutive common stock options average number of common shares outstanding plus dilutive common stock options 1748 1749 outstanding common stock options having no dilutive effect the accompanying notes to consolidated financial statements are an integral part of this statement. abbott laboratories and subsidiaries


(dollars in millions)
December 31
Assets
Current assets:
Cash and cash equivalents
8,522
7,616
Investments, primarily bank time deposits and U.S. treasury bills
Trade receivables, less allowances of — 2025: $
; 2024: $
7,929
6,925
Inventories:
Finished products
3,976
3,700
Work in process
Materials
1,608
1,654
Total inventories
6,488
6,194
Other prepaid expenses and receivables
2,640
2,570
Total current assets
25,996
23,656
Investments
Property and equipment, at cost:
Land
Buildings
4,543
4,207
Equipment
17,571
15,517
Construction in progress
2,567
2,488
25,222
22,740
Less: accumulated depreciation and amortization
13,406
12,082
Net property and equipment
11,816
10,658
Intangible assets, net of amortization
5,526
6,647
Goodwill
24,035
23,108
Deferred income taxes and other assets
18,422
16,459
86,713
81,414
Abbott Laboratories and Subsidiaries

Question: What was Abbott Laboratories's total assets in fiscal year 2025?

what was abbott laboratories's total assets in fiscal year 2025?

what was total assets in fiscal year 2025?

(dollars in millions) december 31 assets current assets: cash and cash equivalents 8522 7616 investments primarily bank time deposits and u.s. treasury bills trade receivables less allowances of — 2025: ; 2024: 7929 6925 inventories: finished products 3976 3700 work in process materials 1608 1654 total inventories 6488 6194 other prepaid expenses and receivables 2640 2570 total current assets 25996 23656 investments property and equipment at cost: land buildings 4543 4207 equipment 17571 15517 construction in progress 2567 2488 25222 22740 less: accumulated depreciation and amortization 13406 12082 net property and equipment 11816 10658 intangible assets net of amortization 5526 6647 goodwill 24035 23108 deferred income taxes and other assets 18422 16459 86713 81414 abbott laboratories and subsidiaries


Question: What was Abbott Laboratories's gross margin in fiscal year 2025?

what was abbott laboratories's gross margin in fiscal year 2025?


Question: What was Abbott Laboratories's net margin in fiscal year 2025?

what was abbott laboratories's net margin in fiscal year 2025?


Question: What was Abbott Laboratories's operating cash flow margin in fiscal year 2025?

what was abbott laboratories's operating cash flow margin in fiscal year 2025?


Question: By what percentage did Abbott Laboratories's net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did abbott laboratories's net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did net income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did Abbott Laboratories's operating income change from fiscal year 2024 to fiscal year 2025?

by what percentage did abbott laboratories's operating income change from fiscal year 2024 to fiscal year 2025?

by what percentage did operating income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did Abbott Laboratories's revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did abbott laboratories's revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did revenue change from fiscal year 2024 to fiscal year 2025?


in millions, except per share data
Fiscal
Net sales
164,683
159,514
152,669
Cost of sales
109,818
106,206
101,709
Gross profit
54,865
53,308
50,960
Operating expenses:
Selling, general and administrative
30,702
28,748
26,598
Depreciation and amortization
3,273
3,034
2,673
Total operating expenses
33,975
31,782
29,271
Operating income
20,890
21,526
21,689
Interest and other (income) expense:
Interest income and other, net
Interest expense
2,412
2,321
1,943
Interest and other, net
2,288
2,120
1,765
Earnings before provision for income taxes
18,602
19,406
19,924
Provision for income taxes
4,446
4,600
4,781
Net earnings
14,156
14,806
15,143
Basic weighted average common shares
Basic earnings per share
14.26
14.96
15.16
Diluted weighted average common shares
1,002
Diluted earnings per share
14.23
14.91
15.11
Fiscal 2025 and fiscal 2023 include 52 weeks. Fiscal 2024 includes 53 weeks.
See accompanying notes to consolidated financial statements.
Fiscal 2025 Form 10-K
Table
of
Contents
THE HOME DEPOT, INC.

Question: What was The Home Depot, Inc.'s net income in fiscal year 2026?

what was net income in fiscal year 2026?

what was the home depot inc.'s net income in fiscal year 2026?

in millions except per share data fiscal net sales 164683 159514 152669 cost of sales 109818 106206 101709 gross profit 54865 53308 50960 operating expenses: selling general and administrative 30702 28748 26598 depreciation and amortization 3273 3034 2673 total operating expenses 33975 31782 29271 operating income 20890 21526 21689 interest and other (income) expense: interest income and other net interest expense 2412 2321 1943 interest and other net 2288 2120 1765 earnings before provision for income taxes 18602 19406 19924 provision for income taxes 4446 4600 4781 net earnings 14156 14806 15143 basic weighted average common shares basic earnings per share 14.26 14.96 15.16 diluted weighted average common shares 1002 diluted earnings per share 14.23 14.91 15.11 fiscal 2025 and fiscal 2023 include 52 weeks. fiscal 2024 includes 53 weeks. see accompanying notes to consolidated financial statements. fiscal 2025 form 10-k table of contents the home depot inc.


Fiscal
in millions
Cash Flows from Operating Activities:
Net earnings
14,156
14,806
15,143
Reconciliation of net earnings to net cash provided by operating activities:
Depreciation and amortization, excluding amortization of intangible assets
3,514
3,336
3,061
Intangible asset amortization
Stock-based compensation expense
Changes in receivables, net
Changes in merchandise inventories
1,498
4,137
Changes in other current assets
Changes in accounts payable and accrued expenses
1,058
1,411
Changes in deferred revenue
Changes in income taxes payable
Changes in deferred income taxes
Other operating activities
Net cash provided by operating activities
16,325
19,810
21,172
Cash Flows from Investing Activities:
Capital expenditures
3,679
3,485
3,226
Payments for businesses acquired, net
5,410
17,644
1,514
Other investing activities
Net cash used in investing activities
8,980
21,031
4,729
Cash Flows from Financing Activities:
Proceeds from short-term debt, net
4,148
Proceeds from long-term debt, net of discounts
2,161
10,010
1,995
Repayments of long-term debt
5,040
1,536
1,271
Repurchases of common stock
7,951
Proceeds from sales of common stock
Cash dividends
9,152
8,929
8,383
Other financing activities
Net cash used in financing activities
7,714
15,443
Change in cash and cash equivalents
1,915
1,000
Effect of exchange rate changes on cash and cash equivalents
Cash and cash equivalents at beginning of year
1,659
3,760
2,757
Cash and cash equivalents at end of year
1,389
1,659
3,760
Supplemental Disclosures:
Cash paid for interest, net of interest capitalized
2,405
2,199
1,809
Non-cash capital expenditures
Non-cash acquisition purchase consideration (
Note 13
Fiscal 2025 and fiscal 2023 include 52 weeks. Fiscal 2024 includes 53 weeks.
See accompanying notes to consolidated financial statements.
Fiscal 2025 Form 10-K
Table
of
Contents
THE HOME DEPOT, INC.

Question: What was The Home Depot, Inc.'s operating cash flow in fiscal year 2026?

net cash provided by used in operating activities

what was operating cash flow in fiscal year 2026?

what was the home depot inc.'s operating cash flow in fiscal year 2026?

fiscal in millions cash flows from operating activities: net earnings 14156 14806 15143 reconciliation of net earnings to net cash provided by operating activities: depreciation and amortization excluding amortization of intangible assets 3514 3336 3061 intangible asset amortization stock-based compensation expense changes in receivables net changes in merchandise inventories 1498 4137 changes in other current assets changes in accounts payable and accrued expenses 1058 1411 changes in deferred revenue changes in income taxes payable changes in deferred income taxes other operating activities net cash provided by operating activities 16325 19810 21172 cash flows from investing activities: capital expenditures 3679 3485 3226 payments for businesses acquired net 5410 17644 1514 other investing activities net cash used in investing activities 8980 21031 4729 cash flows from financing activities: proceeds from short-term debt net 4148 proceeds from long-term debt net of discounts 2161 10010 1995 repayments of long-term debt 5040 1536 1271 repurchases of common stock 7951 proceeds from sales of common stock cash dividends 9152 8929 8383 other financing activities net cash used in financing activities 7714 15443 change in cash and cash equivalents 1915 1000 effect of exchange rate changes on cash and cash equivalents cash and cash equivalents at beginning of year 1659 3760 2757 cash and cash equivalents at end of year 1389 1659 3760 supplemental disclosures: cash paid for interest net of interest capitalized 2405 2199 1809 non-cash capital expenditures non-cash acquisition purchase consideration ( note 13 fiscal 2025 and fiscal 2023 include 52 weeks. fiscal 2024 includes 53 weeks. see accompanying notes to consolidated financial statements. fiscal 2025 form 10-k table of contents the home depot inc.


Question: What was The Home Depot, Inc.'s revenue in fiscal year 2026?

revenue from contract with customer excluding assessed tax

what was the home depot inc.'s revenue in fiscal year 2026?


in millions, except per share data
February 1,
February 2,
Assets
Current assets:
Cash and cash equivalents
1,389
1,659
Receivables, net
5,597
4,903
Merchandise inventories
25,817
23,451
Other current assets
1,588
1,670
Total current assets
34,391
31,683
Net property and equipment
28,021
26,702
Operating lease right-of-use assets
9,204
8,592
Goodwill
22,344
19,475
Intangible assets, net
10,329
8,983
Other assets
Total assets
105,095
96,119
Liabilities and Stockholders’ Equity
Current liabilities:
Short-term debt
4,464
Accounts payable
11,491
11,938
Accrued salaries and related expenses
2,529
2,315
Sales taxes payable
Deferred revenue
2,575
2,610
Income taxes payable
Current installments of long-term debt
4,967
4,582
Current operating lease liabilities
1,418
1,274
Other accrued expenses
4,358
4,166
Total current liabilities
32,424
28,661
Long-term debt, excluding current installments
46,341
48,485
Long-term operating lease liabilities
8,160
7,633
Deferred income taxes
2,845
1,962
Other long-term liabilities
2,512
2,738
Total liabilities
92,282
89,479
Commitments and contingencies (
Note 12
Common stock, par value $
0.05
; authorized:
10,000
shares; issued:
1,802
shares at February 1, 2026 and
1,800
shares at February 2, 2025; outstanding:
shares at February 1, 2026 and
shares at February 2, 2025
Paid-in capital
14,809
14,117
Retained earnings
94,537
89,533
Accumulated other comprehensive loss
1,129
Treasury stock, at cost,
shares at February 1, 2026 and February 2, 2025
95,971
Total stockholders’ equity
12,813
6,640
Total liabilities and stockholders’ equity
105,095
96,119
See accompanying notes to consolidated financial statements.
Fiscal 2025 Form 10-K
Table
of
Contents
THE HOME DEPOT, INC.

Question: What was The Home Depot, Inc.'s total assets in fiscal year 2026?

what was the home depot inc.'s total assets in fiscal year 2026?

what was total assets in fiscal year 2026?

in millions except per share data february 1 february 2 assets current assets: cash and cash equivalents 1389 1659 receivables net 5597 4903 merchandise inventories 25817 23451 other current assets 1588 1670 total current assets 34391 31683 net property and equipment 28021 26702 operating lease right-of-use assets 9204 8592 goodwill 22344 19475 intangible assets net 10329 8983 other assets total assets 105095 96119 liabilities and stockholders' equity current liabilities: short-term debt 4464 accounts payable 11491 11938 accrued salaries and related expenses 2529 2315 sales taxes payable deferred revenue 2575 2610 income taxes payable current installments of long-term debt 4967 4582 current operating lease liabilities 1418 1274 other accrued expenses 4358 4166 total current liabilities 32424 28661 long-term debt excluding current installments 46341 48485 long-term operating lease liabilities 8160 7633 deferred income taxes 2845 1962 other long-term liabilities 2512 2738 total liabilities 92282 89479 commitments and contingencies ( note 12 common stock par value 0.05 ; authorized: 10000 shares; issued: 1802 shares at february 1 2026 and 1800 shares at february 2 2025; outstanding: shares at february 1 2026 and shares at february 2 2025 paid-in capital 14809 14117 retained earnings 94537 89533 accumulated other comprehensive loss 1129 treasury stock at cost shares at february 1 2026 and february 2 2025 95971 total stockholders' equity 12813 6640 total liabilities and stockholders' equity 105095 96119 see accompanying notes to consolidated financial statements. fiscal 2025 form 10-k table of contents the home depot inc.


Question: What was The Home Depot, Inc.'s gross margin in fiscal year 2026?

what was the home depot inc.'s gross margin in fiscal year 2026?


Question: What was The Home Depot, Inc.'s net margin in fiscal year 2026?

what was the home depot inc.'s net margin in fiscal year 2026?


Question: What was The Home Depot, Inc.'s operating cash flow margin in fiscal year 2026?

what was the home depot inc.'s operating cash flow margin in fiscal year 2026?


Question: By what percentage did The Home Depot, Inc.'s net income change from fiscal year 2025 to fiscal year 2026?

by what percentage did net income change from fiscal year 2025 to fiscal year 2026?

by what percentage did the home depot inc.'s net income change from fiscal year 2025 to fiscal year 2026?


Question: By what percentage did The Home Depot, Inc.'s operating income change from fiscal year 2025 to fiscal year 2026?

by what percentage did operating income change from fiscal year 2025 to fiscal year 2026?

by what percentage did the home depot inc.'s operating income change from fiscal year 2025 to fiscal year 2026?

in millions except per share data fiscal net sales 164683 159514 152669 cost of sales 109818 106206 101709 gross profit 54865 53308 50960 operating expenses: selling general and administrative 30702 28748 26598 depreciation and amortization 3273 3034 2673 total operating expenses 33975 31782 29271 operating income 20890 21526 21689 interest and other (income) expense: interest income and other net interest expense 2412 2321 1943 interest and other net 2288 2120 1765 earnings before provision for income taxes 18602 19406 19924 provision for income taxes 4446 4600 4781 net earnings 14156 14806 15143 basic weighted average common shares basic earnings per share 14.26 14.96 15.16 diluted weighted average common shares 1002 diluted earnings per share 14.23 14.91 15.11 fiscal 2025 and fiscal 2023 include 52 weeks. fiscal 2024 includes 53 weeks. see accompanying notes to consolidated financial statements. fiscal 2025 form 10-k table of contents the home depot inc.


Question: By what percentage did The Home Depot, Inc.'s revenue change from fiscal year 2025 to fiscal year 2026?

by what percentage did revenue change from fiscal year 2025 to fiscal year 2026?

by what percentage did the home depot inc.'s revenue change from fiscal year 2025 to fiscal year 2026?


CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(amounts in millions)
52 Weeks Ended
53 Weeks Ended
August 31,
September 1,
September 3,
NET INCOME
8,099
7,367
6,292
Foreign-currency translation adjustment and other, net
COMPREHENSIVE INCOME
8,157
7,344
6,316
The accompanying notes are an integral part of these consolidated financial statements.
COSTCO WHOLESALE CORPORATION

Question: What was Costco Wholesale Corporation's net income in fiscal year 2025?

what was costco wholesale corporation's net income in fiscal year 2025?

what was net income in fiscal year 2025?

(amounts in millions) 52 weeks ended 53 weeks ended august 31 september 1 september 3 net income 8099 7367 6292 foreign-currency translation adjustment and other net comprehensive income 8157 7344 6316 the accompanying notes are an integral part of these consolidated financial statements. costco wholesale corporation


(amounts in millions)
52 Weeks Ended
53 Weeks Ended
August 31,
September 1,
September 3,
CASH FLOWS FROM OPERATING ACTIVITIES
Net income
8,099
7,367
6,292
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
2,426
2,237
2,077
Non-cash lease expense
Stock-based compensation
Impairment of assets and other non-cash operating activities, net
Changes in operating assets and liabilities:
Merchandise inventories
2,068
1,228
Accounts payable
1,938
Other operating assets and liabilities, net
Net cash provided by operating activities
13,335
11,339
11,068
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property and equipment
5,498
4,710
4,323
Purchases of short-term investments
1,028
1,470
1,622
Maturities of short-term investments
1,141
1,790
Other investing activities, net
Net cash used in investing activities
5,311
4,409
4,972
CASH FLOWS FROM FINANCING ACTIVITIES
Repayments of short-term borrowings
Proceeds from short-term borrowings
Repayments of long-term debt
1,077
Proceeds from issuance of long-term debt
Tax withholdings on stock-based awards
Repurchases of common stock
Cash dividend payments
2,183
9,041
1,251
Financing lease payments and other financing activities, net
Net cash used in financing activities
3,775
10,764
2,614
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS
Net change in cash and cash equivalents
4,255
3,794
3,497
CASH AND CASH EQUIVALENTS BEGINNING OF YEAR
9,906
13,700
10,203
CASH AND CASH EQUIVALENTS END OF YEAR
14,161
9,906
13,700
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the year for:
Interest
Income taxes, net
2,917
2,319
2,234
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES:
Cash dividend declared, but not yet paid
Capital expenditures included in liabilities
The accompanying notes are an integral part of these consolidated financial statements.
COSTCO WHOLESALE CORPORATION

Question: What was Costco Wholesale Corporation's operating cash flow in fiscal year 2025?

net cash provided by used in operating activities

what was costco wholesale corporation's operating cash flow in fiscal year 2025?

what was operating cash flow in fiscal year 2025?

(amounts in millions) 52 weeks ended 53 weeks ended august 31 september 1 september 3 cash flows from operating activities net income 8099 7367 6292 adjustments to reconcile net income to net cash provided by operating activities: depreciation and amortization 2426 2237 2077 non-cash lease expense stock-based compensation impairment of assets and other non-cash operating activities net changes in operating assets and liabilities: merchandise inventories 2068 1228 accounts payable 1938 other operating assets and liabilities net net cash provided by operating activities 13335 11339 11068 cash flows from investing activities additions to property and equipment 5498 4710 4323 purchases of short-term investments 1028 1470 1622 maturities of short-term investments 1141 1790 other investing activities net net cash used in investing activities 5311 4409 4972 cash flows from financing activities repayments of short-term borrowings proceeds from short-term borrowings repayments of long-term debt 1077 proceeds from issuance of long-term debt tax withholdings on stock-based awards repurchases of common stock cash dividend payments 2183 9041 1251 financing lease payments and other financing activities net net cash used in financing activities 3775 10764 2614 effect of exchange rate changes on cash and cash equivalents net change in cash and cash equivalents 4255 3794 3497 cash and cash equivalents beginning of year 9906 13700 10203 cash and cash equivalents end of year 14161 9906 13700 supplemental disclosure of cash flow information: cash paid during the year for: interest income taxes net 2917 2319 2234 supplemental disclosure of non-cash activities: cash dividend declared but not yet paid capital expenditures included in liabilities the accompanying notes are an integral part of these consolidated financial statements. costco wholesale corporation


(amounts in millions, except per share data)
52 Weeks Ended
53 Weeks Ended
August 31,
September 1,
September 3,
REVENUE
Net sales
269,912
249,625
237,710
Membership fees
5,323
4,828
4,580
Total revenue
275,235
254,453
242,290
OPERATING EXPENSES
Merchandise costs
239,886
222,358
212,586
Selling, general and administrative
24,966
22,810
21,590
Operating income
10,383
9,285
8,114
OTHER INCOME (EXPENSE)
Interest expense
Interest income and other, net
INCOME BEFORE INCOME TAXES
10,818
9,740
8,487
Provision for income taxes
2,719
2,373
2,195
NET INCOME
8,099
7,367
6,292
NET INCOME PER COMMON SHARE:
Basic
18.24
16.59
14.18
Diluted
18.21
16.56
14.16
Shares used in calculation (000’s)
Basic
443,985
443,914
443,854
Diluted
444,803
444,759
444,452
The accompanying notes are an integral part of these consolidated financial statements.
COSTCO WHOLESALE CORPORATION

Question: What was Costco Wholesale Corporation's revenue in fiscal year 2025?

revenue from contract with customer excluding assessed tax

what was costco wholesale corporation's revenue in fiscal year 2025?

(amounts in millions except per share data) 52 weeks ended 53 weeks ended august 31 september 1 september 3 revenue net sales 269912 249625 237710 membership fees 5323 4828 4580 total revenue 275235 254453 242290 operating expenses merchandise costs 239886 222358 212586 selling general and administrative 24966 22810 21590 operating income 10383 9285 8114 other income (expense) interest expense interest income and other net income before income taxes 10818 9740 8487 provision for income taxes 2719 2373 2195 net income 8099 7367 6292 net income per common share: basic 18.24 16.59 14.18 diluted 18.21 16.56 14.16 shares used in calculation (000's) basic 443985 443914 443854 diluted 444803 444759 444452 the accompanying notes are an integral part of these consolidated financial statements. costco wholesale corporation


(amounts in millions, except par value and share data)
August 31,
September 1,
ASSETS
CURRENT ASSETS
Cash and cash equivalents
14,161
9,906
Short-term investments
1,123
1,238
Receivables, net
3,203
2,721
Merchandise inventories
18,116
18,647
Other current assets
1,777
1,734
Total current assets
38,380
34,246
OTHER ASSETS
Property and equipment, net
31,909
29,032
Operating lease right-of-use assets
2,725
2,617
Other long-term assets
4,085
3,936
TOTAL ASSETS
77,099
69,831
LIABILITIES AND EQUITY
CURRENT LIABILITIES
Accounts payable
19,783
19,421
Accrued salaries and benefits
5,205
4,794
Accrued member rewards
2,677
2,435
Deferred membership fees
2,854
2,501
Other current liabilities
6,589
6,313
Total current liabilities
37,108
35,464
OTHER LIABILITIES
Long-term debt, excluding current portion
5,713
5,794
Long-term operating lease liabilities
2,460
2,375
Other long-term liabilities
2,654
2,576
TOTAL LIABILITIES
47,935
46,209
COMMITMENTS AND CONTINGENCIES
EQUITY
Preferred stock $
0.005
par value;
100,000,000
shares authorized; no shares issued and outstanding
Common stock $
0.005
par value;
900,000,000
shares authorized;
443,237,000
and
443,126,000
shares issued and outstanding
Additional paid-in capital
8,282
7,829
Accumulated other comprehensive loss
1,770
1,828
Retained earnings
22,650
17,619
TOTAL EQUITY
29,164
23,622
TOTAL LIABILITIES AND EQUITY
77,099
69,831
The accompanying notes are an integral part of these consolidated financial statements.
COSTCO WHOLESALE CORPORATION

Question: What was Costco Wholesale Corporation's total assets in fiscal year 2025?

what was costco wholesale corporation's total assets in fiscal year 2025?

what was total assets in fiscal year 2025?

(amounts in millions except par value and share data) august 31 september 1 assets current assets cash and cash equivalents 14161 9906 short-term investments 1123 1238 receivables net 3203 2721 merchandise inventories 18116 18647 other current assets 1777 1734 total current assets 38380 34246 other assets property and equipment net 31909 29032 operating lease right-of-use assets 2725 2617 other long-term assets 4085 3936 total assets 77099 69831 liabilities and equity current liabilities accounts payable 19783 19421 accrued salaries and benefits 5205 4794 accrued member rewards 2677 2435 deferred membership fees 2854 2501 other current liabilities 6589 6313 total current liabilities 37108 35464 other liabilities long-term debt excluding current portion 5713 5794 long-term operating lease liabilities 2460 2375 other long-term liabilities 2654 2576 total liabilities 47935 46209 commitments and contingencies equity preferred stock 0.005 par value; 100000000 shares authorized; no shares issued and outstanding common stock 0.005 par value; 900000000 shares authorized; 443237000 and 443126000 shares issued and outstanding additional paid-in capital 8282 7829 accumulated other comprehensive loss 1770 1828 retained earnings 22650 17619 total equity 29164 23622 total liabilities and equity 77099 69831 the accompanying notes are an integral part of these consolidated financial statements. costco wholesale corporation


Question: What was Costco Wholesale Corporation's gross margin in fiscal year 2025?

what was costco wholesale corporation's gross margin in fiscal year 2025?


Question: What was Costco Wholesale Corporation's net margin in fiscal year 2025?

what was costco wholesale corporation's net margin in fiscal year 2025?


Question: What was Costco Wholesale Corporation's operating cash flow margin in fiscal year 2025?

what was costco wholesale corporation's operating cash flow margin in fiscal year 2025?


Question: By what percentage did Costco Wholesale Corporation's net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did costco wholesale corporation's net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did net income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did Costco Wholesale Corporation's operating income change from fiscal year 2024 to fiscal year 2025?

by what percentage did costco wholesale corporation's operating income change from fiscal year 2024 to fiscal year 2025?

by what percentage did operating income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did Costco Wholesale Corporation's revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did costco wholesale corporation's revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did revenue change from fiscal year 2024 to fiscal year 2025?


Consolidated Statements of Comprehensive Income

(millions)
Net earnings
3,705
4,091
4,138
Other comprehensive income / (loss), net of tax
Pension benefit liabilities
Currency translation adjustment and cash flow hedges
Other comprehensive income / (loss)
Comprehensive income
3,746
4,093
4,097
Note: 2023 consisted of 53 weeks compared with 52 weeks in 2025 and 2024.
See accompanying

Question: What was Target Corporation's net income in fiscal year 2026?

what was net income in fiscal year 2026?

what was target corporation's net income in fiscal year 2026?

(millions) net earnings 3705 4091 4138 other comprehensive income / (loss) net of tax pension benefit liabilities currency translation adjustment and cash flow hedges other comprehensive income / (loss) comprehensive income 3746 4093 4097 note: 2023 consisted of 53 weeks compared with 52 weeks in 2025 and 2024. see accompanying


(millions)
Operating activities
Net earnings
3,705
4,091
4,138
Adjustments to reconcile net earnings to cash provided by operations:
Depreciation and amortization
3,134
2,981
2,801
Share-based compensation expense
Deferred income taxes
Noncash (gains) / losses and other, net
Changes in operating accounts:
Inventory
1,613
Other assets
Accounts payable
1,008
1,216
Accrued and other liabilities
Cash provided by operating activities
6,562
7,367
8,621
Investing activities
Expenditures for property and equipment
3,727
2,891
4,806
Other
Cash used in investing activities
3,649
2,860
4,760
Financing activities
Additions to long-term debt
1,984
Reductions of long-term debt
1,643
1,139
Dividends paid
2,053
2,046
2,011
Repurchase of stock
1,007
Shares withheld for taxes on share-based compensation
Cash used in financing activities
2,187
3,550
2,285
Net increase in cash and cash equivalents
1,576
Cash and cash equivalents at beginning of period
4,762
3,805
2,229
Cash and cash equivalents at end of period
5,488
4,762
3,805
Supplemental information
Interest paid, net of capitalized interest
Leased assets obtained in exchange for new finance lease liabilities
Leased assets obtained in exchange for new operating lease liabilities
1,027
Note: 2023 consisted of 53 weeks compared with 52 weeks in 2025 and 2024.
See accompanying

Question: What was Target Corporation's operating cash flow in fiscal year 2026?

net cash provided by used in operating activities

what was operating cash flow in fiscal year 2026?

what was target corporation's operating cash flow in fiscal year 2026?

(millions) operating activities net earnings 3705 4091 4138 adjustments to reconcile net earnings to cash provided by operations: depreciation and amortization 3134 2981 2801 share-based compensation expense deferred income taxes noncash (gains) / losses and other net changes in operating accounts: inventory 1613 other assets accounts payable 1008 1216 accrued and other liabilities cash provided by operating activities 6562 7367 8621 investing activities expenditures for property and equipment 3727 2891 4806 other cash used in investing activities 3649 2860 4760 financing activities additions to long-term debt 1984 reductions of long-term debt 1643 1139 dividends paid 2053 2046 2011 repurchase of stock 1007 shares withheld for taxes on share-based compensation cash used in financing activities 2187 3550 2285 net increase in cash and cash equivalents 1576 cash and cash equivalents at beginning of period 4762 3805 2229 cash and cash equivalents at end of period 5488 4762 3805 supplemental information interest paid net of capitalized interest leased assets obtained in exchange for new finance lease liabilities leased assets obtained in exchange for new operating lease liabilities 1027 note: 2023 consisted of 53 weeks compared with 52 weeks in 2025 and 2024. see accompanying


(millions, except per share data)
Net sales
104,780
106,566
107,412
Cost of sales
75,511
76,502
77,828
Selling, general, and administrative expenses
21,535
21,969
21,462
Depreciation and amortization (exclusive of depreciation included in cost of sales)
2,617
2,529
2,415
Operating income
5,117
5,566
5,707
Net interest expense
Net other income
Earnings before income taxes
4,767
5,261
5,297
Provision for income taxes
1,062
1,170
1,159
Net earnings
3,705
4,091
4,138
Basic earnings per share
8.16
8.89
8.96
Diluted earnings per share
8.13
8.86
8.94
Weighted average common shares outstanding
Basic
454.1
460.4
461.5
Diluted
455.6
461.8
462.8
Antidilutive shares
Note: 2023 consisted of 53 weeks compared with 52 weeks in 2025 and 2024.
See accompanying

Question: What was Target Corporation's revenue in fiscal year 2026?

revenue from contract with customer excluding assessed tax

what was target corporation's revenue in fiscal year 2026?

(millions except per share data) net sales 104780 106566 107412 cost of sales 75511 76502 77828 selling general and administrative expenses 21535 21969 21462 depreciation and amortization (exclusive of depreciation included in cost of sales) 2617 2529 2415 operating income 5117 5566 5707 net interest expense net other income earnings before income taxes 4767 5261 5297 provision for income taxes 1062 1170 1159 net earnings 3705 4091 4138 basic earnings per share 8.16 8.89 8.96 diluted earnings per share 8.13 8.86 8.94 weighted average common shares outstanding basic 454.1 460.4 461.5 diluted 455.6 461.8 462.8 antidilutive shares note: 2023 consisted of 53 weeks compared with 52 weeks in 2025 and 2024. see accompanying


Consolidated Statements of Financial Position

(millions, except footnotes)
January 31, 2026
February 1, 2025
Assets
Cash and cash equivalents
5,488
4,762
Inventory
12,304
12,740
Other current assets
2,213
1,952
Total current assets
20,005
19,454
Property and equipment, net
33,749
33,022
Operating lease assets
3,703
3,763
Other noncurrent assets
2,033
1,530
Total assets
59,490
57,769
Liabilities and shareholders' investment
Accounts payable
12,622
13,053
Accrued and other current liabilities
6,478
6,110
Current portion of long-term debt and other borrowings
2,130
1,636
Total current liabilities
21,230
20,799
Long-term debt and other borrowings
14,326
14,304
Noncurrent operating lease liabilities
3,462
3,582
Deferred income taxes
2,265
2,303
Other noncurrent liabilities
2,042
2,115
Total noncurrent liabilities
22,095
22,304
Shareholders' investment
Common stock
Additional paid-in capital
7,247
6,996
Retained earnings
9,297
8,090
Accumulated other comprehensive loss
Total shareholders' investment
16,165
14,666
Total liabilities and shareholders' investment
59,490
57,769
Common Stock
Authorized
6,000,000,000
shares, $
0.0833
par value;
452,840,187
shares issued and outstanding as of January 31, 2026;
455,566,995
shares issued and outstanding as of February 1, 2025.
Preferred Stock
Authorized
5,000,000
shares, $
0.01
par value;
no
shares were issued or outstanding during any period presented.
See accompanying

Question: What was Target Corporation's total assets in fiscal year 2026?

what was target corporation's total assets in fiscal year 2026?

what was total assets in fiscal year 2026?

(millions except footnotes) january 31 2026 february 1 2025 assets cash and cash equivalents 5488 4762 inventory 12304 12740 other current assets 2213 1952 total current assets 20005 19454 property and equipment net 33749 33022 operating lease assets 3703 3763 other noncurrent assets 2033 1530 total assets 59490 57769 liabilities and shareholders' investment accounts payable 12622 13053 accrued and other current liabilities 6478 6110 current portion of long-term debt and other borrowings 2130 1636 total current liabilities 21230 20799 long-term debt and other borrowings 14326 14304 noncurrent operating lease liabilities 3462 3582 deferred income taxes 2265 2303 other noncurrent liabilities 2042 2115 total noncurrent liabilities 22095 22304 shareholders' investment common stock additional paid-in capital 7247 6996 retained earnings 9297 8090 accumulated other comprehensive loss total shareholders' investment 16165 14666 total liabilities and shareholders' investment 59490 57769 common stock authorized 6000000000 shares 0.0833 par value; 452840187 shares issued and outstanding as of january 31 2026; 455566995 shares issued and outstanding as of february 1 2025. preferred stock authorized 5000000 shares 0.01 par value; no shares were issued or outstanding during any period presented. see accompanying


Question: What was Target Corporation's gross margin in fiscal year 2026?

what was target corporation's gross margin in fiscal year 2026?


Question: What was Target Corporation's net margin in fiscal year 2026?

what was target corporation's net margin in fiscal year 2026?


Question: What was Target Corporation's operating cash flow margin in fiscal year 2026?

what was target corporation's operating cash flow margin in fiscal year 2026?


Question: By what percentage did Target Corporation's net income change from fiscal year 2025 to fiscal year 2026?

by what percentage did net income change from fiscal year 2025 to fiscal year 2026?

by what percentage did target corporation's net income change from fiscal year 2025 to fiscal year 2026?


Question: By what percentage did Target Corporation's operating income change from fiscal year 2025 to fiscal year 2026?

by what percentage did operating income change from fiscal year 2025 to fiscal year 2026?

by what percentage did target corporation's operating income change from fiscal year 2025 to fiscal year 2026?


Question: By what percentage did Target Corporation's revenue change from fiscal year 2025 to fiscal year 2026?

by what percentage did revenue change from fiscal year 2025 to fiscal year 2026?

by what percentage did target corporation's revenue change from fiscal year 2025 to fiscal year 2026?


In millions
Net income
8,563
8,223
8,469
Other comprehensive income (loss), net of tax
Foreign currency translation adjustments:
Gain (loss) recognized in accumulated other comprehensive
income (AOCI), including net investment hedges
Reclassification of (gain) loss to net income
Foreign currency translation adjustments-net of tax
benefit (expense) of $
), and $
Cash flow hedges:
Gain (loss) recognized in AOCI
Reclassification of (gain) loss to net income
Cash flow hedges-net of tax benefit (expense) of $
), and $
Defined benefit pension plans:
Gain (loss) recognized in AOCI
Reclassification of (gain) loss to net income
Defined benefit pension plans-net of tax benefit (expense)
of $(
, and $
Total other comprehensive income (loss), net of tax
Comprehensive income
8,702
8,127
8,499
See Notes to Consolidated Financial Statements.
McDonald's Corporation
2025 Annual Report

Question: What was McDonald's Corporation's net income in fiscal year 2025?

what was mcdonald's corporation's net income in fiscal year 2025?

what was net income in fiscal year 2025?

in millions net income 8563 8223 8469 other comprehensive income (loss) net of tax foreign currency translation adjustments: gain (loss) recognized in accumulated other comprehensive income (aoci) including net investment hedges reclassification of (gain) loss to net income foreign currency translation adjustments-net of tax benefit (expense) of ) and cash flow hedges: gain (loss) recognized in aoci reclassification of (gain) loss to net income cash flow hedges-net of tax benefit (expense) of ) and defined benefit pension plans: gain (loss) recognized in aoci reclassification of (gain) loss to net income defined benefit pension plans-net of tax benefit (expense) of ( and total other comprehensive income (loss) net of tax comprehensive income 8702 8127 8499 see notes to consolidated financial statements. mcdonald's corporation 2025 annual report


In millions
Years ended December 31,
Operating activities
Net income
8,563
8,223
8,469
Adjustments to reconcile to cash provided by operations
Charges and credits:
Depreciation and amortization
2,199
2,097
1,978
Deferred income taxes
Share-based compensation
Net (gain) loss on sale of restaurant and other businesses
Other
Changes in working capital items:
Accounts receivable
Inventories, prepaid expenses and other current assets
Accounts payable
Income taxes
Other accrued liabilities
Cash provided by operations
10,551
9,447
9,612
Investing activities
Capital expenditures
3,365
2,775
2,357
Purchases of restaurant businesses
Purchases of equity method investments
1,837
Sales of restaurant and other businesses
Sales of property
Other
Cash used for investing activities
3,822
5,346
3,185
Financing activities
Net short-term borrowings
Long-term financing issuances
4,724
2,380
5,221
Long-term financing repayments
4,802
2,777
2,441
Treasury stock purchases
2,056
2,824
3,054
Common stock dividends
5,115
4,870
4,533
Proceeds from stock option exercises
Other
Cash used for financing activities
7,125
7,495
4,374
Effect of exchange rates on cash and equivalents
Cash and equivalents increase (decrease)
3,494
1,996
Cash and equivalents at beginning of year
1,085
4,579
2,584
Cash and equivalents at end of year
1,085
4,579
Supplemental cash flow disclosures
Interest paid
1,555
1,523
1,287
See Notes to Consolidated Financial Statements.
McDonald's Corporation
2025 Annual Report

Question: What was McDonald's Corporation's operating cash flow in fiscal year 2025?

net cash provided by used in operating activities

what was mcdonald's corporation's operating cash flow in fiscal year 2025?

what was operating cash flow in fiscal year 2025?

in millions years ended december 31 operating activities net income 8563 8223 8469 adjustments to reconcile to cash provided by operations charges and credits: depreciation and amortization 2199 2097 1978 deferred income taxes share-based compensation net (gain) loss on sale of restaurant and other businesses other changes in working capital items: accounts receivable inventories prepaid expenses and other current assets accounts payable income taxes other accrued liabilities cash provided by operations 10551 9447 9612 investing activities capital expenditures 3365 2775 2357 purchases of restaurant businesses purchases of equity method investments 1837 sales of restaurant and other businesses sales of property other cash used for investing activities 3822 5346 3185 financing activities net short-term borrowings long-term financing issuances 4724 2380 5221 long-term financing repayments 4802 2777 2441 treasury stock purchases 2056 2824 3054 common stock dividends 5115 4870 4533 proceeds from stock option exercises other cash used for financing activities 7125 7495 4374 effect of exchange rates on cash and equivalents cash and equivalents increase (decrease) 3494 1996 cash and equivalents at beginning of year 1085 4579 2584 cash and equivalents at end of year 1085 4579 supplemental cash flow disclosures interest paid 1555 1523 1287 see notes to consolidated financial statements. mcdonald's corporation 2025 annual report


In millions, except per share data
Years ended December 31,
REVENUES
Revenues from franchised restaurants
16,548
15,715
15,437
Sales by Company-owned and operated restaurants
9,690
9,782
9,742
Other revenues
Total revenues
26,885
25,920
25,494
OPERATING COSTS AND EXPENSES
Franchised restaurants-occupancy expenses
2,618
2,536
2,475
Company-owned and operated restaurant expenses
Food & paper
3,006
2,995
3,039
Payroll & employee benefits
2,905
2,959
2,886
Occupancy & other operating expenses
2,358
2,381
2,299
Other restaurant expenses
Selling, general & administrative expenses
Depreciation and amortization
Other
2,583
2,412
2,435
Other operating (income) expense, net
Total operating costs and expenses
14,492
14,208
13,847
Operating income
12,393
11,712
11,647
Interest expense-net of capitalized interest of $
and $
1,582
1,506
1,361
Nonoperating (income) expense, net
Income before provision for income taxes
10,897
10,345
10,522
Provision for income taxes
2,334
2,121
2,053
Net income
8,563
8,223
8,469
Earnings per common share–basic
12.00
11.45
11.63
Earnings per common share–diluted
11.95
11.39
11.56
Dividends declared per common share
7.17
6.78
6.23
Weighted-average shares outstanding–basic
713.4
718.3
727.9
Weighted-average shares outstanding–diluted
716.4
721.9
732.3
See Notes to Consolidated Financial Statements.
McDonald's Corporation
2025 Annual Report

Question: What was McDonald's Corporation's revenue in fiscal year 2025?

what was mcdonald's corporation's revenue in fiscal year 2025?

in millions except per share data years ended december 31 revenues revenues from franchised restaurants 16548 15715 15437 sales by company-owned and operated restaurants 9690 9782 9742 other revenues total revenues 26885 25920 25494 operating costs and expenses franchised restaurants-occupancy expenses 2618 2536 2475 company-owned and operated restaurant expenses food & paper 3006 2995 3039 payroll & employee benefits 2905 2959 2886 occupancy & other operating expenses 2358 2381 2299 other restaurant expenses selling general & administrative expenses depreciation and amortization other 2583 2412 2435 other operating (income) expense net total operating costs and expenses 14492 14208 13847 operating income 12393 11712 11647 interest expense-net of capitalized interest of and 1582 1506 1361 nonoperating (income) expense net income before provision for income taxes 10897 10345 10522 provision for income taxes 2334 2121 2053 net income 8563 8223 8469 earnings per common share–basic 12.00 11.45 11.63 earnings per common share–diluted 11.95 11.39 11.56 dividends declared per common share 7.17 6.78 6.23 weighted-average shares outstanding–basic 713.4 718.3 727.9 weighted-average shares outstanding–diluted 716.4 721.9 732.3 see notes to consolidated financial statements. mcdonald's corporation 2025 annual report


In millions, except per share data
December 31,
ASSETS
Current assets
Cash and equivalents
1,085
Accounts and notes receivable
2,466
2,383
Inventories, at cost, not in excess of market
Prepaid expenses and other current assets
1,074
Total current assets
4,163
4,599
Other assets
Investments in and advances to affiliates
2,820
2,710
Goodwill
3,354
3,145
Miscellaneous
6,331
6,095
Total other assets
12,505
11,950
Lease right-of-use asset, net
14,606
13,339
Property and equipment
Property and equipment, at cost
49,290
44,177
Accumulated depreciation and amortization
21,049
18,882
Net property and equipment
28,241
25,295
Total assets
59,515
55,182
LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)
Current liabilities
Accounts payable
1,149
1,029
Lease liability
Income taxes
Other taxes
Accrued interest
Accrued payroll and other liabilities
1,488
1,129
Total current liabilities
4,361
3,861
Long-term debt
39,973
38,424
Long-term lease liability
14,147
12,888
Long-term income taxes
Deferred revenues - initial franchise fees
Other long-term liabilities
Deferred income taxes
1,038
1,914
Shareholders’ equity (deficit)
Preferred stock,
no
par value; authorized –
165.0
million shares; issued –
none
Common stock, $
0.01
par value; authorized –
billion shares; issued –
1,660.6
million shares
Additional paid-in capital
9,641
9,281
Retained earnings
70,282
66,834
Accumulated other comprehensive income (loss)
2,414
2,553
Common stock in treasury, at cost;
950.0
and
945.4
million shares
79,316
77,375
Total shareholders’ equity (deficit)
1,791
3,797
Total liabilities and shareholders’ equity (deficit)
59,515
55,182
See Notes to Consolidated Financial Statements.
McDonald's Corporation
2025 Annual Report

Question: What was McDonald's Corporation's total assets in fiscal year 2025?

what was mcdonald's corporation's total assets in fiscal year 2025?

what was total assets in fiscal year 2025?

in millions except per share data december 31 assets current assets cash and equivalents 1085 accounts and notes receivable 2466 2383 inventories at cost not in excess of market prepaid expenses and other current assets 1074 total current assets 4163 4599 other assets investments in and advances to affiliates 2820 2710 goodwill 3354 3145 miscellaneous 6331 6095 total other assets 12505 11950 lease right-of-use asset net 14606 13339 property and equipment property and equipment at cost 49290 44177 accumulated depreciation and amortization 21049 18882 net property and equipment 28241 25295 total assets 59515 55182 liabilities and shareholders' equity (deficit) current liabilities accounts payable 1149 1029 lease liability income taxes other taxes accrued interest accrued payroll and other liabilities 1488 1129 total current liabilities 4361 3861 long-term debt 39973 38424 long-term lease liability 14147 12888 long-term income taxes deferred revenues - initial franchise fees other long-term liabilities deferred income taxes 1038 1914 shareholders' equity (deficit) preferred stock no par value; authorized – 165.0 million shares; issued – none common stock 0.01 par value; authorized – billion shares; issued – 1660.6 million shares additional paid-in capital 9641 9281 retained earnings 70282 66834 accumulated other comprehensive income (loss) 2414 2553 common stock in treasury at cost; 950.0 and 945.4 million shares 79316 77375 total shareholders' equity (deficit) 1791 3797 total liabilities and shareholders' equity (deficit) 59515 55182 see notes to consolidated financial statements. mcdonald's corporation 2025 annual report


Question: What was McDonald's Corporation's net margin in fiscal year 2025?

what was mcdonald's corporation's net margin in fiscal year 2025?


Question: What was McDonald's Corporation's operating cash flow margin in fiscal year 2025?

what was mcdonald's corporation's operating cash flow margin in fiscal year 2025?


Question: By what percentage did McDonald's Corporation's net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did mcdonald's corporation's net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did net income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did McDonald's Corporation's operating income change from fiscal year 2024 to fiscal year 2025?

by what percentage did mcdonald's corporation's operating income change from fiscal year 2024 to fiscal year 2025?

by what percentage did operating income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did McDonald's Corporation's revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did mcdonald's corporation's revenue change from fiscal year 2024 to fiscal year 2025?

by what percentage did revenue change from fiscal year 2024 to fiscal year 2025?


(in millions, except per share data)
Years Ended December 31,
Sales
Products
62,654
59,277
56,265
Services
12,394
11,766
11,306
Total sales
75,048
71,043
67,571
Operating costs and expenses
Products
57,020
54,852
50,206
Services
11,339
10,217
10,027
Impairment and other charges
Other unallocated, net
1,043
1,233
Total operating costs and expenses
67,429
64,113
59,092
Gross profit
7,619
6,930
8,479
Other income, net
Operating profit
7,731
7,013
8,507
Interest expense
1,118
1,036
Non-service FAS pension (expense) income
Other non-operating income, net
Earnings before income taxes
5,922
6,220
8,098
Income tax expense
1,178
Net earnings
5,017
5,336
6,920
Earnings per common share
Basic
21.56
22.39
27.65
Diluted
21.49
22.31
27.55
The accompanying notes are an integral part of these consolidated financial statements.
Lockheed Martin Corporation

Question: What was Lockheed Martin Corporation's net income in fiscal year 2025?

what was lockheed martin corporation's net income in fiscal year 2025?

what was net income in fiscal year 2025?

(in millions except per share data) years ended december 31 sales products 62654 59277 56265 services 12394 11766 11306 total sales 75048 71043 67571 operating costs and expenses products 57020 54852 50206 services 11339 10217 10027 impairment and other charges other unallocated net 1043 1233 total operating costs and expenses 67429 64113 59092 gross profit 7619 6930 8479 other income net operating profit 7731 7013 8507 interest expense 1118 1036 non-service fas pension (expense) income other non-operating income net earnings before income taxes 5922 6220 8098 income tax expense 1178 net earnings 5017 5336 6920 earnings per common share basic 21.56 22.39 27.65 diluted 21.49 22.31 27.55 the accompanying notes are an integral part of these consolidated financial statements. lockheed martin corporation


(in millions)
Years Ended December 31,
Operating activities
Net earnings
5,017
5,336
6,920
Adjustments to reconcile net earnings to net cash provided by operating activities
Depreciation and amortization
1,687
1,559
1,430
Stock-based compensation
Deferred income taxes
Pension settlement charge
Impairment and other charges
Reach-forward losses on select programs
1,615
1,965
Changes in:
Receivables, net
1,550
Contract assets
Inventories
Accounts payable
1,341
Contract liabilities
1,219
Income taxes
Qualified defined benefit pension plans
Other, net
Net cash provided by operating activities
8,557
6,972
7,920
Investing activities
Capital expenditures
1,649
1,685
1,691
Other, net
Net cash used for investing activities
1,977
1,792
1,694
Financing activities
Issuance of long-term debt, net of related costs
1,985
2,970
1,975
Repayments of long-term debt
Repurchases of common stock
3,000
3,700
6,000
Dividends paid
3,131
3,059
3,056
Other, net
Net cash used for financing activities
4,942
4,139
7,331
Net change in cash and cash equivalents
1,638
1,041
1,105
Cash and cash equivalents at beginning of year
2,483
1,442
2,547
Cash and cash equivalents at end of year
4,121
2,483
1,442
The accompanying notes are an integral part of these consolidated financial statements.
Lockheed Martin Corporation

Question: What was Lockheed Martin Corporation's operating cash flow in fiscal year 2025?

net cash provided by used in operating activities

what was lockheed martin corporation's operating cash flow in fiscal year 2025?

what was operating cash flow in fiscal year 2025?

(in millions) years ended december 31 operating activities net earnings 5017 5336 6920 adjustments to reconcile net earnings to net cash provided by operating activities depreciation and amortization 1687 1559 1430 stock-based compensation deferred income taxes pension settlement charge impairment and other charges reach-forward losses on select programs 1615 1965 changes in: receivables net 1550 contract assets inventories accounts payable 1341 contract liabilities 1219 income taxes qualified defined benefit pension plans other net net cash provided by operating activities 8557 6972 7920 investing activities capital expenditures 1649 1685 1691 other net net cash used for investing activities 1977 1792 1694 financing activities issuance of long-term debt net of related costs 1985 2970 1975 repayments of long-term debt repurchases of common stock 3000 3700 6000 dividends paid 3131 3059 3056 other net net cash used for financing activities 4942 4139 7331 net change in cash and cash equivalents 1638 1041 1105 cash and cash equivalents at beginning of year 2483 1442 2547 cash and cash equivalents at end of year 4121 2483 1442 the accompanying notes are an integral part of these consolidated financial statements. lockheed martin corporation


(in millions, except par value)
December 31,
Assets
Current assets
Cash and cash equivalents
4,121
2,483
Receivables, net
3,901
2,351
Contract assets
13,001
12,957
Inventories
3,524
3,474
Other current assets
Total current assets
25,362
21,849
Property, plant and equipment, net
8,875
8,726
Goodwill
11,314
11,067
Intangible assets, net
1,887
2,015
Deferred income taxes
2,975
3,557
Capitalized software
2,417
1,866
Other noncurrent assets
7,010
6,537
Total assets
59,840
55,617
Liabilities and equity
Current liabilities
Accounts payable
3,630
2,222
Salaries, benefits and payroll taxes
3,184
3,125
Contract liabilities
11,440
9,795
Current maturities of long-term debt
1,168
Other current liabilities
3,913
3,635
Total current liabilities
23,335
19,420
Long-term debt, net
20,532
19,627
Accrued pension liabilities
3,915
4,791
Other noncurrent liabilities
5,337
5,446
Total liabilities
53,119
49,284
Stockholders’ equity
Common stock, $
par value per share
Additional paid-in capital
Retained earnings
14,034
14,551
Accumulated other comprehensive loss
7,542
8,452
Total stockholders’ equity
6,721
6,333
Total liabilities and equity
59,840
55,617
The accompanying notes are an integral part of these consolidated financial statements.
Lockheed Martin Corporation

Question: What was Lockheed Martin Corporation's total assets in fiscal year 2025?

what was lockheed martin corporation's total assets in fiscal year 2025?

what was total assets in fiscal year 2025?

(in millions except par value) december 31 assets current assets cash and cash equivalents 4121 2483 receivables net 3901 2351 contract assets 13001 12957 inventories 3524 3474 other current assets total current assets 25362 21849 property plant and equipment net 8875 8726 goodwill 11314 11067 intangible assets net 1887 2015 deferred income taxes 2975 3557 capitalized software 2417 1866 other noncurrent assets 7010 6537 total assets 59840 55617 liabilities and equity current liabilities accounts payable 3630 2222 salaries benefits and payroll taxes 3184 3125 contract liabilities 11440 9795 current maturities of long-term debt 1168 other current liabilities 3913 3635 total current liabilities 23335 19420 long-term debt net 20532 19627 accrued pension liabilities 3915 4791 other noncurrent liabilities 5337 5446 total liabilities 53119 49284 stockholders' equity common stock par value per share additional paid-in capital retained earnings 14034 14551 accumulated other comprehensive loss 7542 8452 total stockholders' equity 6721 6333 total liabilities and equity 59840 55617 the accompanying notes are an integral part of these consolidated financial statements. lockheed martin corporation


Question: By what percentage did Lockheed Martin Corporation's net income change from fiscal year 2024 to fiscal year 2025?

by what percentage did lockheed martin corporation's net income change from fiscal year 2024 to fiscal year 2025?


Question: By what percentage did Lockheed Martin Corporation's operating income change from fiscal year 2024 to fiscal year 2025?

by what percentage did lockheed martin corporation's operating income change from fiscal year 2024 to fiscal year 2025?